Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.64 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.64 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.64 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.47 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.43 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4042291 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Fumaric Acid SCHEMBL4337403 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Maleic Acid SCHEMBL27498394 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Fumaric Acid SCHEMBL4337405 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Fumaric Acid SCHEMBL4042292 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Fumaric Acid SCHEMBL2390060 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Fumaric Acid SCHEMBL4400079 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Fumaric Acid SCHEMBL10458273 | 0.97 | TSHR (0.60) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Maleic Acid SCHEMBL29222106 | 0.97 | TSHR (0.60) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Maleic Acid SCHEMBL27558801 | 0.94 | TSHR (0.56) | TSHRLMNAEGLN1TP53ALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344919-A1 | PROCESS FOR THE PREPARATION OF PREGABALIN | HIKAL LIMITED (IN) | 2015-12-03 | — | — | US | claimed |
| EP-2916832-A2 | A PROCESS FOR THE PREPARATION OF PREGABALIN | Hikal Limited (IN) | 2015-09-16 | — | — | EP | claimed |
| WO-2014072785-A2 | A PROCESS FOR THE PREPARATION OF PREGABALIN | HIKAL LIMITED (IN) | 2014-05-15 | — | — | WO | claimed |
| WO-2013190357-A1 | A PROCESS FOR THE PREPARATION OF GABAPENTIN | HIKAL LIMITED (IN) | 2013-12-27 | — | — | WO | claimed |
| US-20110237626-A1 | COMPOSITIONS FOR HYGIENIC HAND DISINFECTION AND DISINFECTANT HANDWASHING | AIR LIQUIDE SANTE (INTERNATIONAL) (FR) | 2011-09-29 | — | — | US | claimed |
| EP-1032574-B1 | INDOLO 2,1-b|QUINAZOLE-6,12-DIONE ANTIMALARIAL COMPOUNDS AND METHODS OF TREATING MALARIA THEREWITH | US ARMY (US) | 2007-06-13 | — | — | EP | claimed |
| US-20030191138-A1 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | UNITED STATES ARMY | 2003-10-09 | — | — | US | claimed |
| US-6531487-B2 | Water solubility; bioavailability | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2003-03-11 | — | — | US | claimed |
| US-20010034350-A1 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | UNITED STATES ARMY | 2001-10-25 | — | — | US | claimed |
| US-6284772-B1 | OR PRODRUG THEREOF | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2001-09-04 | — | — | US | claimed |
| EP-1032574-A3 | INDOLO 2,1-b]QUINAZOLE-6,12-DIONE ANTIMALARIAL COMPOUNDS AND METHODS OF TREATING MALARIA THEREWITH | WRAIR (Walter Reed Army Institute of Research) (US) | 2000-12-20 | — | — | EP | claimed |
| EP-1032574-A2 | INDOLO 2,1-b]QUINAZOLE-6,12-DIONE ANTIMALARIAL COMPOUNDS AND METHODS OF TREATING MALARIA THEREWITH | WRAIR (Walter Reed Army Institute of Research) (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000018769-A2 | INDOLO[2,1-b]QUINAZOLE-6,12-DIONE ANTIMALARIAL COMPOUNDS AND METHODS OF TREATING MALARIA THEREWITH | WRAIR (WALTER REID ARMY INSTITUTE OF RESEARCH) (US) | 2000-04-06 | — | — | WO | claimed |
| WO-1983003352-A1 | ORAL COMPOSITION IN THE FORM OF A COMBINED IRON-BACTERIA PREPARATRION PARTICULARLY INTENDED FOR TREATING ANIMALS | KVANTA, ENDRE | 1983-10-13 | — | — | WO | claimed |
| US-4060623-A | 1,2,4-Triazole antimycotic compositions and use thereof | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | claimed |
| US-4038406-A | 1,2,4-TRIAZOLE ANTIMYCOTIC COMPOSITIONS AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-26 | — | — | US | claimed |
| US-4036966-A | 1,2,4-Triazole antimycotic compositions and use thereof | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | claimed |
| US-4036967-A | 1,2,4-Triazole antimycotic compositions and use thereof | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | claimed |
| WO-2024074678-A1 | PROCESS FOR PROCESSING POLYMER-CONTAINING MATERIALS | Plantics Holding B.V. (NL) | 2024-04-11 | — | — | WO | disclosed |
| US-4686273-A | Process for preparing modified poly(alkylene carbonate) polyahls | THE DOW CHEMICAL COMPANY (US) | 1987-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191138-A1 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | HCCS, DAO, SCO2 | TSHR 3389/4885LMNA 1643/4885EGLN1 131/4885 |
| US-20110237626-A1 | COMPOSITIONS FOR HYGIENIC HAND DISINFECTION AND DISINFECTANT HANDWASHING | DHCR24, DEGS1, ADH1C | TSHR 3617/4885LMNA 4403/4885EGLN1 195/4885 |
| US-20010034350-A1 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | HCCS, DAO, SCO2 | TSHR 3389/4885LMNA 1643/4885EGLN1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.